Health Related Quality of Life After Video Assisted Thoracoscopic Lobectomy for Lung Cancer
To test the effect of post operative complications on the health related quality of life (HRQOL) after Video Assisted Thoracoscopic Surgery (VATS) for Non-Small Cell Lung Cancer (NSCLC).
The HRQOL of patients with early stage NSCLC will be assessed at baseline (before surgery) using 3 different reliable and valid HRQOL questionnaire (SF-36, EQ-5D and QLQ30/13), then at regular intervals in the early post-operative period (2,4,8 and 12 weeks) the HRQOL will be assessed using the same questionnaires to determine the difference between patients with low/no post operative complications to those with high grade post-operative complications.
Post operative complications will be assess while the patients in the hospital on a daily basis using the Clavien classification system for surgical complications.
Operable Early Stage NSCLC by the VATS Approach
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
- Health related Quality of life [ Time Frame: Change in health related quality of life at 2 weeks. Change of Health Related Quality of Life at 4 weeks. Change in Health Related Quality of Life at 8 weeks. Change in Health Related Quality of Life at 12 weeks. ] [ Designated as safety issue: No ]Health Related Quality of Life will be assessed using the SF-36, EQ-5D and QLQ30/13 questionnaires.
|Study Start Date:||March 2011|
|Estimated Study Completion Date:||March 2012|
Patients who had VATS lung resection for NSCLC, and have no or low grade (grade 1 and 2) post operative complications based on the Clavien classification system.
Patients who had VATS lung resection for NSCLC, and have no or high grade (grade 3 and 4) post operative complications based on the Clavien classification system.
|Contact: Sayf Gazala, MD||780 628 email@example.com|
|Royal Alexandra Hospital||Recruiting|
|Edmonton, Alberta, Canada, T5H 3V9|
|Contact: Patricia Thompson, CCRP 780 735 4096 firstname.lastname@example.org|
|Principal Investigator: Eric Bedard, MD, FRCSC|